Figure 3.
The summary of the efficacy of tocilizumab in phase III randomized controlled trials in RA patients.
Notes: Cochrane review summarized the efficacy of tocilizumab (TCZ) from eight randomized controlled trials.42 These forest plots demonstrate odds ratio of achieving ACR 50 response rate. Efficacy of 8 mg/kg TCZ as monotherapy or in combination with MTX was significantly better than placebo or MTX in achieving ACR 50 response rates. Although the efficacy of 4 mg/kg TCZ monotherapy was not superior to MTX, that of 4 mg/kg with MTX can overcome MTX.